A. Stewart Campbell

Chief Executive Officer

Dr. Campbell joined Axial Therapeutics in 2017 and was appointed the company’s Chief Executive Officer in February 2021. Dr. Campbell has played a fundamental role in the company’s growth and strategy over the last 4 years. He brings more than 25 years of experience leading and building teams that have strong track records of discovering and developing novel therapeutics for the patients who need them.Prior to joining Axial, Dr. Campbell held various leadership roles at biopharmaceutical and chemical manufacturing companies, including Corden Pharma, Surface Logix and Insmed Inc.At Corden Pharma, Dr. Campbell served as Head of Product Management and Business Development for Carbohydrates and Lipids and as Head of Operations for Corden Pharma’s Woburn, MA manufacturing site.Prior to Corden Pharma, Dr. Campbell served as Vice President of R&D at Ancora Pharmaceuticals, successfully triaging the company through the acquisition and integration process by Corden Pharma. While at Surface Logix and Insmed, he played an integral role in the discovery and development of five clinical-stage drug candidates, including the Rho kinase inhibitor belumosudil (Rezurock™) and TAK-607 (rIGF-1/BP-3). During his career, Dr. Campbell has been a co-inventor on more than 20 issued patents.


He holds a B.S. with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada) and completed his post-doctoral research at Duke University.

Federico Bolognani, M.D., PH.D.

Vice President and Head, Clinical Science

Dr. Bolognani brings to Axial Therapeutics over 20 years of experience in translational neuroscience research in academia, pharmaceutical and the biotechnology industries. Most recently, he served as the Vice President and Head of Clinical Science at VectivBio in Basel, Switzerland. Prior to VectivBio AG, Dr. Bolognani was Vice President and Head of Clinical Science at Therachon AG, which was acquired by Pfizer in 2019. Prior to Therachon, Dr. Bolognani held various senior-level positions at Roche. As Translation Medicine Leader, Dr. Bolognani led several of Roche’s programs in neuroscience, including the successful Phase 2 Balovaptan program in autism spectrum disorder (ASD), which was granted Breakthrough Designation in 2018. Dr. Bolognani received his Ph.D. and M.D. degrees from Universidad Nacional de La Plata, Argentina and has an extensive scientific publication record in translational neuroscience research.

Chris Meyer

Vice President, Operations

Mr. Meyer has more than 20 years of biopharma development experience, with an emphasis on program management, CMC, and process development. He has built and led teams both in the U.S. and Europe that were involved in a variety of programs from early-stage development through to commercial launch and supply. As Vice President of Operations at Axial Therapeutics, he is responsible for Program Management and Clinical Operations. Currently, Mr. Meyer is focused on executing Axial’s clinical trials in both autism and Parkinson’s disease. Prior to joining Axial, he held various roles at companies, including Lonza, Momenta, OvaScience, and Alkermes. He holds a B.S. in Mechanical Engineering from Worcester Polytechnic Institute (WPI) and an M.B.A. in International Business from Northeastern University.

Maura Moroni

Vice President, Finance

Ms. Moroni joined Axial in August 2019 and brings more than 20 years of corporate finance and accounting experience. She previously served as Controller at Eloxx Pharmaceuticals. Earlier in her career, she was a Senior Director at CFGI, a financial consulting firm, where she spent five years providing operational support to clients in the life sciences industry including Juniper Pharmaceuticals and Aveo Pharmaceutical. Ms. Moroni began her career at Arthur Andersen. She holds an M.B.A./M.S.A. in Accounting from Northeastern University and a B.A. from the College of the Holy Cross and holds Certified Public Accountant status in Massachusetts.

Jeffrey Young

Chief Financial Officer

Mr. Young brings over 20 years of finance and capital markets experience, an extensive background in financial planning and operations, management and strategy, and a deep knowledge of the life sciences sector. Mr. Young most recently served as CFO, Treasurer and Secretary at Juniper Pharmaceuticals, Inc., where he played an instrumental role in Juniper’s acquisition by Catalent. Prior to that, Mr. Young served as CFO and Treasurer of OvaScience, a global fertility company focused on new treatment options for women. Mr. Young was previously the CFO and Treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients. Before that, he served as CFO and Treasurer at Lantheus Medical Imaging, where he led and managed multiple public debt offerings.

Mr. Young began his career holding various positions of increasing responsibility in finance at Critical Therapeutics, PerkinElmer, Inc. and PriceWaterhouseCoopers LLP.  Mr. Young holds a Bachelor of Science in Business Administration from Georgetown University.